Fig. 3From: Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthmaRisk ratio for percentage who experience 0 exacerbations among adultsBack to article page